123 related articles for article (PubMed ID: 16729730)
41. High-throughput screening for kinase inhibitors.
von Ahsen O; Bömer U
Chembiochem; 2005 Mar; 6(3):481-90. PubMed ID: 15742384
[TBL] [Abstract][Full Text] [Related]
42. Consensus scoring for protein-ligand interactions.
Feher M
Drug Discov Today; 2006 May; 11(9-10):421-8. PubMed ID: 16635804
[TBL] [Abstract][Full Text] [Related]
43. High-throughput X-ray crystallography for drug discovery.
Blundell TL; Patel S
Curr Opin Pharmacol; 2004 Oct; 4(5):490-6. PubMed ID: 15351354
[TBL] [Abstract][Full Text] [Related]
44. The 'retro-design' concept for novel kinase inhibitors.
Müller G; Sennhenn PC; Woodcock T; Neumann L
IDrugs; 2010 Jul; 13(7):457-66. PubMed ID: 20582870
[TBL] [Abstract][Full Text] [Related]
45. Selectivity assessment of kinase inhibitors: strategies and challenges.
Luo Y
Curr Opin Mol Ther; 2005 Jun; 7(3):251-5. PubMed ID: 15977423
[TBL] [Abstract][Full Text] [Related]
46. Proteus in the world of proteins: conformational changes in protein kinases.
Rabiller M; Getlik M; Klüter S; Richters A; Tückmantel S; Simard JR; Rauh D
Arch Pharm (Weinheim); 2010 Apr; 343(4):193-206. PubMed ID: 20336692
[TBL] [Abstract][Full Text] [Related]
47. Structure-based development of target-specific compound libraries.
Orry AJ; Abagyan RA; Cavasotto CN
Drug Discov Today; 2006 Mar; 11(5-6):261-6. PubMed ID: 16580603
[TBL] [Abstract][Full Text] [Related]
48. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design.
Davis AM; Teague SJ; Kleywegt GJ
Angew Chem Int Ed Engl; 2003 Jun; 42(24):2718-36. PubMed ID: 12820253
[TBL] [Abstract][Full Text] [Related]
49. Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases.
Cox KJ; Shomin CD; Ghosh I
Future Med Chem; 2011 Jan; 3(1):29-43. PubMed ID: 21428824
[TBL] [Abstract][Full Text] [Related]
50. Recent developments in the discovery of protein kinase inhibitors from the urea class.
Dumas J; Smith RA; Lowinger TB
Curr Opin Drug Discov Devel; 2004 Sep; 7(5):600-16. PubMed ID: 15503863
[TBL] [Abstract][Full Text] [Related]
51. Rational ligand-based virtual screening and structure-activity relationship studies in the ligand-binding domain of the glucocorticoid receptor-α.
Onnis V; Kinsella GK; Carta G; Fayne D; Lloyd DG
Future Med Chem; 2009 Jun; 1(3):483-99. PubMed ID: 21426128
[TBL] [Abstract][Full Text] [Related]
52. The many roles of computation in drug discovery.
Jorgensen WL
Science; 2004 Mar; 303(5665):1813-8. PubMed ID: 15031495
[TBL] [Abstract][Full Text] [Related]
53. Preparation of kinase-biased compounds in the search for lead inhibitors of kinase targets.
Lai JY; Langston S; Adams R; Beevers RE; Boyce R; Burckhardt S; Cobb J; Ferguson Y; Figueroa E; Grimster N; Henry AH; Khan N; Jenkins K; Jones MW; Judkins R; Major J; Masood A; Nally J; Payne H; Payne L; Raphy G; Raynham T; Reader J; Reader V; Reid A; Ruprah P; Shaw M; Sore H; Stirling M; Talbot A; Taylor J; Thompson S; Wada H; Walker D
Med Res Rev; 2005 May; 25(3):310-30. PubMed ID: 15593285
[TBL] [Abstract][Full Text] [Related]
54. Chemical genetic approaches to kinase drug discovery.
Gallion SL; Qian D
Curr Opin Drug Discov Devel; 2005 Sep; 8(5):638-45. PubMed ID: 16159026
[TBL] [Abstract][Full Text] [Related]
55. Structural interaction fingerprints: a new approach to organizing, mining, analyzing, and designing protein-small molecule complexes.
Singh J; Deng Z; Narale G; Chuaqui C
Chem Biol Drug Des; 2006 Jan; 67(1):5-12. PubMed ID: 16492144
[TBL] [Abstract][Full Text] [Related]
56. Target-biased scoring approaches and expert systems in structure-based virtual screening.
Jansen JM; Martin EJ
Curr Opin Chem Biol; 2004 Aug; 8(4):359-64. PubMed ID: 15288244
[TBL] [Abstract][Full Text] [Related]
57. The role of structure in kinase-targeted inhibitor design.
Pratt DJ; Endicott JA; Noble ME
Curr Opin Drug Discov Devel; 2004 Jul; 7(4):428-36. PubMed ID: 15338952
[TBL] [Abstract][Full Text] [Related]
58. Pharmacophore modeling and applications in drug discovery: challenges and recent advances.
Yang SY
Drug Discov Today; 2010 Jun; 15(11-12):444-50. PubMed ID: 20362693
[TBL] [Abstract][Full Text] [Related]
59. Novel scoring methods in virtual ligand screening.
Pick D
Methods Mol Biol; 2004; 275():439-48. PubMed ID: 15141125
[TBL] [Abstract][Full Text] [Related]
60. Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly.
Erlanson DA; Hansen SK
Curr Opin Chem Biol; 2004 Aug; 8(4):399-406. PubMed ID: 15288250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
